SCHEMBL4346759

SCHEMBL4346759

Oc1ccc(NCc2ccccc2Sc2ccc(Cl)c(Cl)c2)c(O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
HTR1A P08908 1/20 0.39
HTR3A P46098 1/20 0.39
MAPT P10636 5/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
G6PD P11413 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
RECQL P46063 1/20 0.38
CCR6 P51684 1/20 0.38
MCL1 Q07820 1/20 0.38
HKDC1 Q2TB90 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GFER P55789 1/20 0.38
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348367 0.88 SLC6A4 (0.46) SMN1; SMN2MAPTKDM4EALDH1A1G6PD
SCHEMBL4357675 0.86 MAPT (0.44) SMN1; SMN2MAPTKDM4EALDH1A1G6PD
SCHEMBL4358394 0.86 SLC6A4 (0.50) SMN1; SMN2MAPTKDM4EALDH1A1G6PD
SCHEMBL4359292 0.85 HTR1A (0.40) SMN1; SMN2HTR1AHTR3AMAPTHPGD
SCHEMBL4353649 0.85 SMN1; SMN2 (0.48) SMN1; SMN2MAPTKDM4EALDH1A1G6PD
SCHEMBL4351207 0.83 MEN1 (0.40) SMN1; SMN2HTR1AHTR3AMAPTKDM4E
SCHEMBL4342198 0.83 MAPT (0.48) SMN1; SMN2MAPTKDM4EALDH1A1G6PD
SCHEMBL4356022 0.81 MEN1 (0.42) SMN1; SMN2HTR1AHTR3AMAPTKDM4E
SCHEMBL4357669 0.81 GAA (0.40) SMN1; SMN2HTR1AHTR3AMAPTKDM4E
SCHEMBL4342478 0.81 HTR1A (0.39) SMN1; SMN2HTR1AHTR3AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885HTR1A 1211/4885HTR3A 1091/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885HTR1A 1434/4885HTR3A 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.